ArticleBrain communications2026
Elevated serum inflammasome adaptor protein ASC is associated with white matter hyperintensities in vascular cognitive impairment.
Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) and vascular dementia (VaD) exhibit distinct neuropathological hallmarks, with AD defined by cortical amyloid plaques and neurofibrillary tangles, while VaD arises primarily from cerebrovascular disease (CeVD). However, CeVD frequently coexists with AD, and both conditions fall within the spectrum of vascular cognitive impairment (VCI). Notably, chronic neuroinflammation is a shared mechanistic link between AD and VaD. Inflammasomes, multi-protein complexes that sense cellular damage and orchestrate inflammatory responses, have been implicated in preclinical models of both diseases. However, their translational potential in the clinical setting remains underexplored. Here, we investigate the inflammasome adaptor protein, apoptosis associated speck-like protein containing a CARD (ASC), as a novel serum biomarker for CeVD, cognitive decline and VCI progression. A total of 531 participants (123 non-cognitively impaired, 208 cognitive impaired, no dementia and 200 with dementia) were included from a Singapore-based clinical cohort. All subjects underwent comprehensive clinical, neuropsychological and neuroimaging assessments. Serum samples were collected, and ASC was measured using a microfluidics immunoassay platform. Compared to controls, serum ASC levels were increased in the VCI clinical subgroups, namely, cognitive impaired, no dementia with CeVD, AD with CeVD and VaD. Multivariate analyses using CeVD neuroimaging markers showed associations between serum ASC and white matter hyperintensities, but not with lacunes or cerebral microbleeds. Mediation analyses similarly showed that the association between ASC and VCI subgroups may be largely explainable by severity of concomitant CeVD, specifically white matter hyperintensities volume. Our findings indicate that elevated serum ASC levels may reflect a state of inflammasome activation in VCI, particularly in individuals with extensive white matter hyperintensities. These results underscore the potential role of dysregulated inflammasome activation not only as a pathogenic factor but also as a potential therapeutic target for VCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.